한글목차

규제 약물 시장은 2025년에 460억 달러로 추정되고, 2032년에는 643억 달러에 이를 전망이며, 2025-2032년 연평균 성장률(CAGR) 4.9%로 성장이 예측되고 있습니다.

세계의 규제 약물 시장은 제약업계 중에서도 고도로 규제된 전문 분야입니다. 규제 약물이란 남용이나 의존 가능성이 있는 약물을 말하며, 따라서 정부의 엄격한 규제의 대상이 되고 있습니다. 이러한 물질은 의료 용도, 남용 가능성, 안전성 프로파일에 따라 다양한 일정으로 분류됩니다.

시장 역학 :

세계의 규제 약물 시장 시장 역학은 다양한 요인의 영향을 받고 있습니다. 시장 성장 촉진요인으로는 만성 질환 증가, 통증 관리약에 대한 수요 증가, 노인 인구 증가 등을 들 수 있습니다. 한편, 엄격한 정부 규제, 약물 남용 및 중독 위험, 연구 개발 비용의 높은 수준 등이 시장의 억제 요인이 되고 있습니다.

그러나 시장에는 성장 기회도 있습니다. 신규 약물 전달 시스템 개발, 기술의 진보, 맞춤형 의료에 대한 주목의 고조가 시장 성장의 원동력이 될 것으로 예측됩니다. 게다가 신흥국에서의 의료 인프라 확대 및 정신질환에 대한 의식 고조는 시장 관계자에게 새로운 길을 개척하는 것입니다.

결론적으로, 세계의 규제 약물 시장은 제약 업계에서 고도로 규제되고 전문화된 분야입니다. 시장 역학은 정부 규제, 시장 성장 촉진요인, 억제요인, 기회 등 다양한 요인의 영향을 받고 있습니다. 시장의 주요 기업은 통증 관리 및 만성 질환 치료 수요 증가에 대응하기 위해 규제 약물의 연구 개발 및 유통에 주력하고 있습니다.

본 조사의 주요 특징

• 세계의 규제 약물 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측 기간(2025-2032년) 시장 규모 및 복합연간 성장률(CAGR%)을 제공합니다.
• 또한 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 인사이트도 제공합니다.
• 엔터프라이즈 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 매개변수를 기반으로 세계 규제 약물 시장의 주요 기업 프로파일을 제공합니다.
• 이 보고서의 인사이트를 통해 마케팅 담당자 및 기업 경영진은 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
• 세계의 규제 약물 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자는 세계의 규제 약물 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사 결정이 용이해집니다.

목차

제1장 조사 목적 및 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의 및 범위
• 주요 요약
• 일관된 기회 지도(COM)

제3장 시장 역학, 규제 및 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• 주요 하이라이트
• 규제 시나리오
• 최근 동향
• 제품 출시 및 승인
• PEST 분석
• Porter's Five Forces 분석
• 합병, 인수 및 제휴

제4장 세계의 규제 약물 시장 : 코로나 바이러스(COVID-19) 유행의 영향

• COVID-19 역학
• 공급측 및 수요측 분석
• 경제에 미치는 영향

제5장 세계의 규제 약물 시장 : 약제 클래스별(2020-2032년)

• 오피오이드
• 각성제
• 진정제
• 환각제
• 단백 동화 스테로이드
• 기타

제6장 세계의 규제 약물 시장 : 용도별(2020-2032년)

• 통증 관리
• 불안
• 불면증
• 기침 방지
• 주의 결함 다동성 장애(ADHD)
• 나루코렙시
• 기타

제7장 세계의 규제 약물 시장 : 판매 채널별(2020-2032년)

• 병원 및 진료소
• 약국
• 기타(학술 연구 기관 등)

제8장 세계의 규제 약물 시장 : 지역별(2020-2032년)

• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 스페인
  • 프랑스
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 한국
  • ASEAN
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 멕시코
  • 기타 라틴아메리카
• 중동
  • GCC 국가
  • 이스라엘
  • 기타 중동
• 아프리카
  • 남아프리카
  • 북아프리카
  • 중앙 아프리카

제9장 경쟁 구도

• 기업 프로파일
  • Johnson &Johnson Services, Inc.
  • Pfizer Inc.
  • Sanofi
  • Merck &Co., Inc.
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Novartis Pharmaceuticals Corporation
  • AbbVie Inc.
  • GSK Plc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Teva Pharmaceutical Inc.
  • Bayer AG
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International GmbH
  • Aspen Holdings
  • Astellas Pharma Inc.
• 애널리스트의 견해

제10장 섹션

• 참고문헌
• 조사 방법
• 출판사에 대해

영문목차

Controlled Substance Market is estimated to be valued at USD 46.00 Bn in 2025 and is expected to reach USD 64.3 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.9% from 2025 to 2032.

The global controlled substance market is a highly regulated and specialized sector within the pharmaceutical industry. Controlled substances are drugs that have the potential for abuse and dependence, and are therefore subject to strict government regulations. These substances are classified into different schedules based on their medical use, potential for abuse, and safety profile.

Market Dynamics:

The market dynamics of the global controlled substance market are influenced by various factors. The drivers of the market include the increasing prevalence of chronic diseases, rising demand for pain management drugs, and the growing geriatric population. On the other hand, the market is restrained by stringent government regulations, the risk of drug abuse and addiction, and the high cost of research and development.

However, the market also presents opportunities for growth. The development of novel drug delivery systems, advancements in technology, and the increasing focus on personalized medicine are expected to drive market growth. Additionally, the expansion of healthcare infrastructure in emerging economies and the growing awareness about mental health disorders are creating new avenues for market players.

In conclusion, the global controlled substance market is a highly regulated and specialized sector within the pharmaceutical industry. The market dynamics are influenced by various factors, including government regulations, market drivers, restraints, and opportunities. The key players in the market are focused on research, development, and distribution of controlled substances to meet the growing demand for pain management and chronic disease treatment.

Key features of the study:

• This report provides in-depth analysis of the global controlled substance market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global controlled substance market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Pfizer, Sanofi, Merck & Co., Gilead Sciences, Amgen, Novartis, AbbVie, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Teva Pharmaceutical, Bayer, Novo Nordisk, Allergan, Takeda Pharmaceutical, Boehringer Ingelheim, Aspen Pharmacare, and Astellas Pharma. These companies are involved in the research, development, manufacturing, and distribution of controlled substances
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global controlled substance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global controlled substance market

Detailed Segmentation:

• Global Controlled Substance Market, By Drug Type:
  • Opioids
  • Stimulants
  • Depressants
  • Hallucinogens
  • Anabolic Steroids
• Global Controlled Substance Market, By Application:
  • Pain Management
  • Anxiety
  • Insomnia
  • Cough Suppression
  • ADHD
  • Narcolepsy
• Global Controlled Substance Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Controlled Substance Market, By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles:
  • Johnson & Johnson
  • Pfizer
  • Sanofi
  • Merck & Co.
  • Gilead Sciences
  • Amgen
  • Novartis
  • AbbVie
  • GlaxoSmithKline
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • Teva Pharmaceutical
  • Bayer
  • Novo Nordisk
  • Allergan
  • Takeda Pharmaceutical
  • Boehringer Ingelheim
  • Aspen Pharmacare
  • Astellas Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Application
  • Market Snippet, By Sales Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Controlled Substance Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Controlled Substance Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Opioids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Stimulants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Depressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Hallucinogens
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Anabolic Steroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global Controlled Substance Market, By Application, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Pain Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Anxiety
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Insomnia
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Cough Suppression
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Attention Deficit Hyperactivity Disorder (ADHD)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Narcolepsy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Global Controlled Substance Market, By Sales Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2023and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Hospitals & Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others (Academic & Research Institutes, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Controlled Substance Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2023and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Sales Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region , 2020-2032, (US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Company Profile
  • Johnson & Johnson Services, Inc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Pfizer Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Sanofi
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Merck & Co., Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Gilead Sciences, Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Amgen Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Novartis Pharmaceuticals Corporation
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • AbbVie Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • GSK Plc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • AstraZeneca
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Bristol-Myers Squibb Company
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Eli Lilly and Company
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Teva Pharmaceutical Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Bayer AG
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Novo Nordisk A/S
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Takeda Pharmaceutical Company Limited
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Boehringer Ingelheim International GmbH
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Aspen Holdings
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
  • Astellas Pharma Inc.
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Analysts' Views

10. Section

• References
• Research Methodology
• About us